PDF
Full
Outline
Objective To investigate hepatitis B virus (HBV) reactivation in patients with diffuse large B-cell lymphoma (DLBCL) who were hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive (HBsAg negative/anti-HBc positive) and received rituximab combined with CHOP (R-CHOP) chemotherapy regimen. Methods In this retrospective study, clinical data of 187 HBsAg negative/anti-HBc positive patients with DLBCL were collated and analyzed respectively from Hematology Department of Peking University Third Hospital from 2010 to 2018. All the patients received R-CHOP chemotherapy and did not receive prophylactic antiviral therapy. According to whether HBV was reactivated or not, these patients were divided into non-HBV reactivation group (174 cases) and HBV reactivation group (13 cases). Results The age of the patients in HBV reactivation group was significantly higher than that in non-HBV reactivation group [71(66, 80) years vs. 65(54, 75) years, P<0.05]. HBV DNA changed from undetectable baseline to detectable level in 13 patients (13/13, 100.0%). The time when HBsAg or HBeAg became positive in 2 patients was earlier than the time when HBV DNA could be detected. In 13 patients with HBV reactivation, 2 patients developed hepatitis related to HBV reactivation, and there was no fulminant hepatitis related to HBV reactivation. Serum HBsAg became positive in 7 of the 13 patients (7/13, 53.8%) with HBV reactivation, whereas serum HBeAg became positive in 3 patients (3/13, 23.1%). After HBV reactivation, HBV DNA reached an undetectable level again in 10 patients during follow-up, of which 7 patients received antiviral treatment. HBsAg became negative again in 2 HBsAg positive patients during follow-up. Conclusion DLBCL patients who were HBsAg negative/anti-HBc positive and treated with R-CHOP chemotherapy had a moderate risk of HBV reactivation. Close monitoring of HBV DNA levels and HBV serological markers should be performed in lymphoma patients who received R-CHOP chemotherapy.
PDF
234
114
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
